Related Experiment Video
Updated: Mar 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
The Regulation of Biosimilars in Latin America
Ricardo Garcia1, Denizar Vianna Araujo2
1Latin American Center for Biological Research (CLAPBio), Rua São José, 696, Alto da Boa Vista, São Paulo, SP, Brazil, ZIP 04739-001. ricardogarcia@clapbio.com.
Abstract:
This article summarizes the regulatory scenario on biological medications in Latin America focusing on comparability studies, extrapolation of indications, interchangeability and pharmacovigilance issues. In the case of comparability studies, what is being discussed is the possibility of decreasing the clinical trials requirement, but that the molecule should be well characterized in the studies of pharmacokinetics and pharmacodynamics. With the worldwide-level approval of the first monoclonal antibody biosimilar, infliximab, extrapolation of indications are being discussed, since the behavior of the Latin America regulatory agencies has been different with regard to such issue. Another issue discussed by the regulatory agencies is the interchangeability between biological medications and their biosimilars, mainly due to the fact that there is a clear confusion on interchangeability and substitution concepts. Finally, the pharmacovigilance debate, according to what takes place globally, is related to the need for identifying and differentiating the reference biological medication and its biosimilars for traceability purposes.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
Bioequivalence studies: Biowaivers
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence: Overview

